A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

This study is testing a type of immune cell therapy called CAR-T cells — where a patient's own immune cells are modified to attack cancer — for blood cancers that have returned or stopped responding to treatment and have spread to the central nervous system (brain and spinal cord). **You may be eligible if...** - You are between 3 and 70 years old - You have been diagnosed with a relapsed or treatment-resistant B-cell leukemia or lymphoma that has spread to the central nervous system - Your leukemia cells carry the CD19 marker on their surface - Prior standard chemotherapy has not worked or your disease has relapsed at least twice **You may NOT be eligible if...** - You have active, uncontrolled infection (including HIV or hepatitis) - You have severe organ dysfunction (heart, liver, kidneys) - You are pregnant or breastfeeding - You have had a prior CAR-T cell therapy that caused severe reactions Talk to your doctor to see if this trial is right for you.